ELOVL1-IN-1

Research use only, not for human use.

ELOVL1-IN-1 is an ELOVL1 inhibitor. ELOVL1-IN-1 can reduce the levels of very long chain fatty acids. ELOVL1-IN-1 can be used in the study of adrenoleukodystrophy (ALD).

ELOVL1-IN-1 is an ELOVL1 inhibitor. ELOVL1-IN-1 can reduce the levels of very long chain fatty acids. ELOVL1-IN-1 can be used in the study of adrenoleukodystrophy (ALD).(In Vitro):Administration of 1 nM-10 μM ELOVL1-IN-1 for 48 h reduces the level of VLCFA, lysophosphatidylcholine (LPC) in adrenoleukodystrophy (ALD) patient fibroblasts and healthy human fibroblasts, ALD patient B‐lymphocytes, and human microglia.(In Vivo):Oral dministration of ELOVL1-IN-1 reduces of a VLCFA level, specifically C26:0 LPC level in blood of ABCD1 knockout mice (0.5-64 mg/kg; 28 days), wild‐type (WT) rats (30-300 mg/kg; 7 days), and cynomolgous monkeys (30 mg/kg; 7 days).

ELOVL1-IN-1 (compound 87) (1 nM-10 μM; 48 h) reduces the the level of VLCFA, lysophosphatidylcholine (LPC) in adrenoleukodystrophy (ALD) patient fibroblasts and healthy human fibroblasts, ALD patient B‐lymphocytes, and human microglia.

ELOVL1-IN-1 (compound 87) reduces of a VLCFA level, specifically C26:0 LPC level in blood of ABCD1 knockout (KO) mice (0.5-64 mg/kg; p.o. once daily for 28 days), wild‐type (WT) rats (30-300 mg/kg; p.o. once daily for 7 days), and cynomolgous monkeys (30 mg/kg; p.o. once daily for 7 days).

1-(2-Fluorophenyl)-N-(1-(2-fluoropyridin-4-YL)-1H-pyrazol-3-YL)cyclopropane-1-carboxamide

Others

Other Targets

AhR

——

——

2227482-41-7

340.33

C18H14F2N4O

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (293.83 mM)

O=C(C1(CC1)c(cccc1)c1F)Nc(cc1)nn1-c1cc(F)ncc1

——

(-20℃)

With Ice Pack

≥ 2 years